Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
This article was originally published in The Pink Sheet Daily & The Rose Sheet
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.
You may also be interested in...
Being successful with products originally marketed by the other will be key to the future growth and bragging rights for two leading European Big Pharmas, GlaxoSmithKline and Novartis.
Rosiglitazone will be available under a Risk Evaluation and Mitigation Strategy with restricted distribution pending an independent panel's re-adjudication of CV endpoints in the much-maligned, open-label RECORD study.
The number of new drugs that launched in 2021 was on par with recent high trends, but launch trajectories generally underwhelmed commercially – except for COVID-19 vaccines.